You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 64 No. 6, June 2007 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (2)
 •Contact me when this article is cited
 Related Content
 •Related letters
 •Similar articles in this journal
 Topic Collections
 •Substance Abuse/ Alcoholism
 •Neurology
 •Cognitive Disorders
 •Psychiatry, Other
 •Public Health
 •Alert me on articles by topic

Cognition in Novice Ecstasy Users With Minimal Exposure to Other Drugs

A Prospective Cohort Study

Thelma Schilt, MSc; Maartje M. L. de Win, MD, PhD; Maarten Koeter, PhD; Gerry Jager, PhD; Dirk J. Korf, PhD; Wim van den Brink, MD, PhD; Ben Schmand, PhD

Arch Gen Psychiatry. 2007;64(6):728-736.

Context  Ecstasy (street name for [±]-3,4-methylenedioxymethamphetamine [MDMA]) use has been associated with cognitive deficits, especially in verbal memory. However, owing to the cross-sectional and retrospective nature of currently available studies, questions remain regarding the causal direction and clinical relevance of these findings.

Objective  To examine the relationship between Ecstasy use and subsequent cognitive performance.

Design  A prospective cohort study in Ecstasy-naive subjects with a high risk for future first Ecstasy use, as part of the Netherlands XTC Toxicity study. The initial examination took place between April 10, 2002, and April 28, 2004; follow-up was within 3 years after the initial examination.

Setting and Participants  One hundred eighty-eight healthy Ecstasy-naive volunteers (mean age, 22 years) were recruited. Of these, 58 subjects started using Ecstasy (mean cumulative dose, 3.2 tablets; median cumulative dose, 1.5 tablets). They were compared with 60 persistent Ecstasy-naive subjects matched on age, sex, intelligence, and use of substances other than Ecstasy. Differences in cognition between Ecstasy users and Ecstasy-naive subjects were adjusted for differences in cannabis and other recreational drug use.

Main Outcome Measures  Change scores between the initial examination and follow-up on neurocognitive tests measuring attention, working memory, verbal and visual memory, and visuospatial ability.

Results  At the initial examination, there were no statistically significant differences in any of the neuropsychological test scores between persistent Ecstasy-naive subjects and future Ecstasy users. However, at follow-up, change scores on immediate and delayed verbal recall and verbal recognition were significantly lower in the group of incident Ecstasy users compared with persistent Ecstasy-naive subjects. There were no significant differences on other test scores.

Conclusions  Our findings suggest that even a first low cumulative dose of Ecstasy is associated with decline in verbal memory. Although the performance of the group of incident Ecstasy users is still within the normal range and the immediate clinical relevance of the observed deficits is limited, long-term negative consequences cannot be excluded.


Author Affiliations: Amsterdam Institute for Addiction Research (Ms Schilt and Drs Koeter and van den Brink), Amsterdam, the Netherlands; Departments of Psychiatry (Ms Schilt and Drs Koeter and van den Brink), Radiology (Dr de Win), and Neurology (Dr Schmand), Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; Rudolf Magnus Institute of Neuroscience, Department of Psychiatry, University Medical Centre, Utrecht, the Netherlands (Dr Jager); and Bonger Institute of Criminology (Dr Korf) and Department of Psychology (Dr Schmand), University of Amsterdam, Amsterdam, the Netherlands.


RELATED LETTERS

No Evidence of Decrease in Cognitive Function in Users of Low-Dose Ecstasy
Teri S. Krebs and Pål-Ørjan Johansen
Arch Gen Psychiatry. 2008;65(2):236.
EXTRACT | FULL TEXT  

No Evidence of Decrease in Cognitive Function in Users of Low-Dose Ecstasy—Reply
Thelma Schilt, Maartje M. de Win, Maarten Koeter, Gerry Jager, Dirk J. Korf, Wim van den Brink, and Ben Schmand
Arch Gen Psychiatry. 2008;65(2):236-237.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

No Evidence of Decrease in Cognitive Function in Users of Low-Dose Ecstasy
Krebs and Johansen
Arch Gen Psychiatry 2008;65:236-236.
FULL TEXT  

No Evidence of Decrease in Cognitive Function in Users of Low-Dose Ecstasy--Reply
Schilt et al.
Arch Gen Psychiatry 2008;65:236-237.
FULL TEXT  

"Why Do You Think They Call It Dope?"
JWatch Psychiatry 2007;2007:3-3.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.